^
Association details:
Biomarker:MYC overexpression
Cancer:Non Small Cell Lung Cancer
Drug:MRT-2359 (GSPT1 degrader)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

3929 / 3 - Identification of MRT-2359 a potent, selective and orally bioavailable GSPT1-directed molecular glue degrader (MGD) for the treatment of cancers with Myc-induced translational addiction

Published date:
03/09/2022
Excerpt:
...oral administration of MRT-2359 in high N-Myc NSCLC xenografts and PDXs led to complete intratumoral GSPT1 degradation and concomitant decrease in N-Myc protein levels, resulting in tumor regression.